四川科伦药业股份有限公司 2015 年年度报告全文 四川科伦药业股份有限公司 2015 年年度报告 2016 年 03 月 1 四川科伦药业股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人刘革新、主管会计工作负责人赖德贵及会计机构负责人(会计主管人员)黄俊 声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司年度报告所涉及未来计划等前瞻性陈述不构成公司对投资者的实质承诺，投资者及 相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 公司可能面临行业政策变化风险、生产要素上涨的风险、快速发展引致的风险、募集资 金投资项目实施的风险、固定资产折旧增加导致利润下降的风险等，敬请广大投资者注意投 资风险。详细内容见本报告"第四节九、（四）公司面临的风险及应对措施"。 公司经本次董事会审议通过的利润分配预案为：以 1,432,518,933 股（以 2015 年 1 ...

1 四川科伦药业股份有限公司 2015 年第三季度报告正文 第一节 重要提示 四川科伦药业股份有限公司 2015 年第三季度报告正文 证券代码：002422 证券简称：科伦药业 公告编号：2015-102 四川科伦药业股份有限公司 2015 年第三季度报告正文 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人刘革新、主管会计工作负责人赖德贵及会计机构负责人(会计主管人员)黄俊声明：保证季 度报告中财务报表的真实、准确、完整。 2 四川科伦药业股份有限公司 2015 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 22,241,561,499.00 | 21,202,835,316. ...

四川科伦药业股份有限公司 2015 年半年度报告全文 四川科伦药业股份有限公司 2015 年半年度报告 2015 年 08 月 0 四川科伦药业股份有限公司 2015 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 3 四川科伦药业股份有限公司 2015 年半年度报告全文 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人刘革新、主管会计工作负责人赖德贵及会计机构负责人(会计主 管人员)黄俊声明：保证本半年度报告中财务报告的真实、准确、完整。 公司可能面临行业政策变化风险、生产要素上涨的风险、快速发展引致的 风险、固定资产折旧增加导致利润下降的风险、环保风险、汇率风险等，敬请 广大投资者注意投资风险。 1 | 目录 | | --- | | 2015 | 半年度报告 0 | | --- | --- | | 第一节 | 重要提示、目录和释义 1 | | 第二节 | 公司简介 6 | | 第三节 | 会计 ...

Financial Performance - The company's operating revenue for Q1 2015 was ¥1,892,650,277, a decrease of 2.46% compared to ¥1,940,287,290 in the same period last year[8]. - Net profit attributable to shareholders was ¥205,906,729, down 9.66% from ¥227,925,878 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥193,191,271, reflecting a decline of 10.01% compared to ¥214,690,729 in the previous year[8]. - Basic and diluted earnings per share were both ¥0.29, a decrease of 9.38% from ¥0.32 in the previous year[8]. - The net profit attributable to shareholders for the first half of 2015 is expected to be between RMB 45.635 million and RMB 53.688 million, representing a decrease of 0.00% to 15.00% compared to the same period in 2014[21]. Cash Flow and Assets - The net cash flow from operating activities decreased by 18.03%, amounting to ¥61,723,002, down from ¥75,302,437 in the same period last year[8]. - Total assets at the end of the reporting period were ¥21,541,134,693, representing a 1.60% increase from ¥21,202,835,316 at the end of the previous year[8]. - Net assets attributable to shareholders increased by 1.83% to ¥10,936,296,449 from ¥10,739,478,348 at the end of the previous year[8]. Expenses and Liabilities - Financial expenses increased by 45.12% due to higher bank interest from increased financing and exchange losses from currency depreciation[16]. - Investment income decreased by 44.50% to ¥610,638 from ¥1,100,225 due to reduced profits from joint ventures[16]. - Other current liabilities rose by 73.30% from RMB 1.49 billion to RMB 2.58 billion, attributed to the reclassification of bonds payable[17]. - The company reported a 100% increase in non-current liabilities due within one year, from RMB 50 million to RMB 100 million, due to the reclassification of long-term loans[17]. - The company’s bond payables decreased by 37.73% from RMB 2.88 billion to RMB 1.80 billion, also due to reclassification[17]. Operational Challenges - The company faced temporary operational losses due to the phased shutdown and production limits at Yili Chuan Ning Biotech Co., which is undergoing project upgrades[21]. - The company’s KAZ Pharmaceuticals faced increased losses due to low production and sales volumes while awaiting the completion of drug tenders in Kazakhstan[21]. Investments and Acquisitions - Kolun International acquired 145,300,000 shares of Lijun International Pharmaceutical (控股)有限公司 at HKD 2.75 per share, totaling HKD 399,575,000, equivalent to RMB 313,891,129[23]. - As of March 31, 2015, the fair value of Kolun International's shares in Lijun International was RMB 390,157,395 based on real-time stock prices from the Hong Kong Stock Exchange[23]. Future Outlook - The company anticipates continued growth in the production and sales of infusion and non-infusion products in the first half of 2015[21]. - The company’s financing net amount increased, leading to higher borrowing interest and exchange losses for subsidiaries[21]. Legal and Compensation - The company’s actual controller committed to compensate for any compensation or liability incurred due to ongoing litigation[20].

Financial Performance - The company reported a significant increase in revenue, with total revenue reaching 5.2 billion CNY, representing a year-on-year growth of 15%[14]. - The company's operating revenue for 2014 was CNY 8,023,421,289, representing a 17.45% increase compared to CNY 6,831,281,981 in 2013[23]. - The net profit attributable to shareholders for 2014 was CNY 1,001,902,613, a decrease of 7.19% from CNY 1,079,521,586 in 2013[23]. - The net cash flow from operating activities increased by 16.03% to CNY 1,218,735,938 in 2014, up from CNY 1,050,373,845 in 2013[23]. - The total assets at the end of 2014 were CNY 21,202,835,316, an increase of 18.14% from CNY 17,946,851,434 at the end of 2013[23]. - The company's net assets attributable to shareholders rose by 10.04% to CNY 10,739,478,348 at the end of 2014, compared to CNY 9,759,926,168 at the end of 2013[23]. - The company achieved a sales revenue of 8.023 billion yuan in 2014, representing a year-on-year growth of 17.45%[37]. - The gross profit margin for the pharmaceutical manufacturing sector was 42.87%, with a year-on-year increase of 16.60% in revenue[84]. - The company's operating costs increased by 24.13% to CNY 4.61 billion, with the pharmaceutical manufacturing sector accounting for 98.51% of these costs[76]. - The company's total operating costs amounted to CNY 4,607,806,540, representing a 24.13% increase compared to CNY 3,712,055,490 in 2013[78]. Dividend Policy - The company plans to distribute a cash dividend of 2.50 CNY per 10 shares (including tax) based on a total share capital of 720,000,000 shares as of December 31, 2014[4]. - The cash dividend for 2014 represents 17.97% of the net profit attributable to shareholders, which was CNY 1,001,902,613[155]. - The company has implemented a cash dividend distribution plan for three consecutive years since its listing in June 2010, with a total cash dividend of CNY 120 million in 2010, CNY 120 million in 2011, and CNY 180 million in 2014[151][152][155]. - The company has not proposed any capital reserve fund conversion to increase share capital in the recent years, maintaining a clear cash dividend policy[153][155]. - The company’s cash dividend payout ratio has consistently exceeded the requirements set forth in its articles of association, ensuring shareholder returns are prioritized[153]. Research and Development - The company is investing in new product development, with a pipeline that includes 10 new drugs expected to launch in the next two years[14]. - The company is committed to research and development of high-tech drugs, including generic drugs and innovative small molecule drugs[32]. - The company invested 389 million yuan in R&D in 2014, with 5 new Class 3.1 drugs registered as the first in China[36][38]. - The company has a total of 1,144 patents, including 126 invention patents, 792 utility model patents, and 226 design patents[33]. - The company has 240 ongoing A-class projects, including 194 brand generic drugs and 17 innovative small molecules[39]. - The company plans to enhance its R&D capabilities by establishing new research centers in key regions[14]. - The company’s R&D center has become one of the most powerful in the domestic pharmaceutical industry, enhancing its competitive edge[94]. - The company is focusing on strengthening its R&D capabilities in brand generic drugs, innovative small molecule drugs, and biotechnology drugs[133]. Market Strategy and Expansion - The company is focusing on expanding its market presence, particularly in the biopharmaceutical sector, to enhance its competitive edge[14]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach[14]. - The company aims to develop a competitive advantage in the entire antibiotic industry chain through innovative development and utilization of natural resources[32]. - The company is committed to a "three-driving" development strategy, focusing on technology upgrades and differentiated competition[36]. - The company plans to establish a research team in the United States, marking its first step towards global expansion[96]. - The company aims to optimize group resources and adapt to the national pharmaceutical system reform through these expansion and upgrade projects[119]. - The company plans to enhance its production capacity and market competitiveness through strategic investments in new technologies and facilities[119]. Compliance and Governance - The company has maintained a stable governance structure and is continuously improving its management capabilities[32]. - The company has actively engaged in social responsibility initiatives, as detailed in its 2014 Social Responsibility Report, which covers governance, safety, and environmental efforts[156]. - The company is classified as a heavy polluting industry according to national environmental protection regulations, and it has complied with relevant environmental laws[157]. - The company faced administrative penalties from the China Securities Regulatory Commission during the reporting period, with details available in the relevant sections of the report[158]. - The company has committed to strictly adhere to securities laws and the Shenzhen Stock Exchange listing rules regarding related party transactions[194]. - The company has established a dedicated team to oversee compliance and reporting processes to mitigate risks associated with regulatory violations[194]. - The company has taken steps to ensure accurate and complete disclosures in future financial reports[194]. Risks and Challenges - The company has identified potential risks including industry policy changes and rising production costs, which may impact future profitability[14]. - The company faces risks from industry policy changes, including uncertainties in bidding processes and potential disruptions in pricing strategies, which may affect market expansion[142]. - Rising production costs due to stricter drug production standards and increased raw material prices pose a risk to the company's operational costs, prompting a focus on cost control measures[142]. - The pharmaceutical industry is expected to face continued price reduction risks and slower growth in 2015, with increased marketization of policies[128]. - The company is preparing for the comprehensive launch of new products such as dual-chamber bags and sodium acetate electrolyte injection solutions, aiming for rapid user acceptance post-launch[141]. Environmental and Social Responsibility - The company emphasizes "environmental priority and sustainable development" in its antibiotic intermediate project, aiming to balance economic and environmental benefits[145]. - The revised Environmental Protection Law, effective from January 1, 2015, imposes stricter regulations on environmental protection, which the company must comply with to avoid legal repercussions[144]. - The company has completed the strategic layout of its infusion production bases nationwide and aims to finalize the antibiotic full industry chain by 2015[143]. Related Party Transactions - The total amount of related party transactions with Kelong Medical Group in 2014 was approximately 720 million CNY, with an actual occurrence of 716.43 million CNY[175]. - The company engaged in related party transactions amounting to 80.17 million RMB with Guangbo Company, accounting for 55.22% of similar transactions[173]. - The company also had related party transactions of 2.79 million RMB with Yibei Coal, representing 62.98% of similar transactions[173]. - The company provided a guarantee for Kelong Doosan's bank loan of 7 million CNY, with a total approved guarantee amount of 20 million CNY[184]. - The company has a non-operating related party debt of 12 million CNY with Guangbo Company, which was reduced by 6 million CNY during the year, leaving a balance of 6 million CNY[178]. Legal Matters - The company reported a contract dispute with Chengdu Jiasheng Energy Co., Ltd., involving a claim for 44 million RMB, with a court ruling confirming the validity of the investment agreement[163]. - The company is in the process of enforcing a court ruling requiring Chengdu Jiasheng to return the 44 million RMB loan and pay interest calculated at the People's Bank of China loan rate[163]. - The company reported a loss of 50 million RMB due to a lawsuit with Chengdu Jiaseng, which was dismissed by the court[164]. - The company received a final ruling to pay 27 million RMB to Mayshan Biopharmaceutical Engineering for a technology licensing fee[173].

Financial Performance - The company reported a revenue of 1.2 billion yuan for the first half of 2014, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders was 200 million yuan, up 10% compared to the same period last year[19]. - The company achieved a revenue of CNY 3.97 billion in the reporting period, representing a year-on-year increase of 24.70%[20]. - Net profit attributable to shareholders was CNY 536.88 million, a slight increase of 0.47% compared to the same period last year[20]. - The company reported a diluted earnings per share of CNY 1.12, reflecting a 0.90% increase year-on-year[20]. - The company reported a significant increase in investment income, rising by 989.28% to ¥2,268,156 from ¥208,225[35]. - The net profit from the Pearl Pharmaceutical (Anyue branch) Phase II expansion project was CNY 4.5528 million, which is below the expected project benefits due to market environment changes[79]. - The net profit from the Yueyang project in Hunan was lower than expected due to the short production time and gradual capacity release[80]. - The net profit from the Guangdong Kelong expansion project was lower than expected due to actual sales prices being below projections and the project not yet reaching full production capacity[87]. Research and Development - The company plans to invest 300 million yuan in R&D for new products and technologies in the upcoming year[19]. - The company holds 1,203 patents, including 144 invention patents, and has been recognized as a national high-tech enterprise[29]. - The company has 209 ongoing research projects, with 55 new projects initiated in 2014, including intravenous drugs and innovative drug delivery technologies[37]. - The company plans to submit approximately 30 additional projects in the second half of 2014, with a focus on oncology and nutritional supplements[38]. - The company plans to enhance its product structure and continue R&D in infusion products to maintain its leading position in the market[32]. - The company has established a complete R&D system from raw material synthesis to project registration, enhancing its research capabilities[65]. Market Expansion and Strategy - User data indicates a growth in customer base by 20%, reaching 1 million active users[19]. - The company has expanded its market presence by entering two new provinces, aiming for a 25% increase in market share[19]. - A strategic acquisition of a local pharmaceutical company was completed, expected to enhance production capacity by 30%[19]. - New product launches are scheduled for Q4 2014, targeting a market penetration rate of 15% within the first year[19]. - The company is actively expanding its market presence by promoting high-margin soft plastic packaging infusion products and developing new markets such as private hospitals[50]. - The company is facing potential risks from rising production costs and regulatory changes in the pharmaceutical industry[3]. Financial Management and Investments - The board has decided not to distribute cash dividends for this fiscal year, focusing on reinvestment strategies[3]. - The company has established a significant investment plan post-IPO to support its strategic development and enhance its competitive position in the antibiotic industry[61]. - The company has invested a total of ¥316,902,932.50 in external investments during the reporting period, compared to ¥0.00 in the same period last year[67]. - The total amount of raised funds is ¥478,884.23 million, with ¥454,890.93 million already invested cumulatively[75]. - The company has a bank deposit balance of ¥38,747.67 million in its fundraising special account as of June 30, 2014[75]. - The company has redirected unused fundraising from various projects to the high-end soft packaging production line and supporting warehouse projects to improve fundraising efficiency[80]. Regulatory and Compliance Issues - The company is currently under investigation by the China Securities Regulatory Commission for alleged information disclosure violations[30]. - The company has taken corrective measures in response to the China Securities Regulatory Commission's directives regarding information disclosure and related party transactions[107]. - The company received an administrative penalty from the China Securities Regulatory Commission on June 3, 2014, for failing to disclose related party transactions, with fines imposed on the company and responsible individuals[110]. - The company has identified three related parties during the special inspection, and the accounting treatment of related transactions will not have a significant impact on the disclosed financial statements[99]. Shareholder and Governance Matters - The profit distribution plan for 2013 includes a cash dividend of RMB 2.50 per 10 shares and a capital reserve transfer of 5 shares for every 10 shares held, approved by the shareholders' meeting on May 21, 2014[100]. - The profit distribution plan was implemented on July 1, 2014, ensuring compliance with company regulations and protecting minority shareholders' rights[101]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[103]. - The company has committed to ensuring that its major shareholders do not engage in competitive businesses[135]. - The company has a commitment to provide priority purchase rights for any business opportunities that may compete with its main operations[135]. Operational Performance - The total assets at the end of the reporting period reached CNY 19.14 billion, up 6.65% from the previous year[20]. - The company has completed the construction of several production lines, including the high-end soft packaging production line with an investment of CNY 39,744.21 million[78]. - The company has achieved a 100% investment progress in its polypropylene infusion bag production line expansion project[77]. - The company has implemented lean management across ten production facilities, achieving a 70% implementation rate of 5S practices and reducing costs by several million RMB[52]. - The company is focusing on quality management improvements post-GMP certification, ensuring product safety and quality through enhanced training and internal audits[51].

证券代码：002422 证券简称：科伦药业 公告编号：2014-070 四川科伦药业股份有限公司 2014 年第三季度报告正文 四川科伦药业股份有限公司 2014 年第三季度报告正文 1 四川科伦药业股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人刘革新、主管会计工作负责人赖德贵及会计机构负责人(会计主管人员)赖德贵声明：保证 季度报告中财务报表的真实、准确、完整。 2 除下列董事外，其他董事亲自出席了审议本次季报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 程志鹏 董事 出差 潘慧 于明德 董事 出差 刘思川 四川科伦药业股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | ...

Financial Performance - The company reported a revenue of 1.2 billion CNY for the first half of 2014, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders was 200 million CNY, up 10% compared to the same period last year[19]. - The company achieved a revenue of CNY 3,967,165,098, representing a year-on-year increase of 24.70%[20]. - Net profit attributable to shareholders was CNY 536,876,748, a slight increase of 0.47% compared to the previous year[20]. - The company reported a diluted earnings per share of CNY 1.12, reflecting a 0.90% increase year-on-year[20]. - The company reported a significant increase in investment income, rising by 989.28% to ¥2,268,156 from ¥208,225[35]. - The net profit from the Pearl Pharmaceutical (Anyue Branch) Phase II expansion project was CNY 4.5528 million, which is lower than the expected benefits outlined in the prospectus[79]. - The net profit from the Yueyang project in Hunan was lower than expected due to the short production time and gradual capacity release[80]. - The net profit attributable to shareholders for the first three quarters of 2014 is expected to range from 84,876,000 to 101,851,000 CNY, representing a change of 0.00% to 20.00% compared to the same period in 2013[96]. Research and Development - The company plans to invest 300 million CNY in R&D for new drug development in the upcoming year[19]. - The company has 209 ongoing research projects, with 55 new projects initiated in 2014, including intravenous drugs and innovative drug delivery technologies[37]. - The company plans to submit approximately 30 new projects in the second half of 2014, with 16 projects already submitted in the first half[38]. - The company holds 1,203 patents, including 144 invention patents, and has been recognized as a national high-tech enterprise[29]. - The company plans to enhance its product structure and continue R&D in infusion products to maintain its leading position in the market[32]. - The company has established a complete R&D system from raw material synthesis to project registration, enhancing its research and development efficiency[65]. - The research institute currently has over 340 drug researchers, including 34 PhDs and 121 master's degree holders, with plans to expand to over 1,000 personnel in the next 2-3 years[65]. Market Expansion - User data indicates a 20% increase in the number of prescriptions filled for the company's products in the first half of 2014[19]. - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 25%[19]. - The company is actively expanding its market presence in new packaging types, such as PP soft bags, to stabilize overall gross margins despite competitive pricing pressures in the infusion market[50]. - The company has received registration approvals for new infusion products, including PP bags, from several production bases, laying a solid foundation for product upgrades[54]. - The company is currently under investigation by the China Securities Regulatory Commission for alleged information disclosure violations[30]. Financial Management - The company has no plans to distribute cash dividends for this fiscal year, focusing instead on reinvestment[3]. - Future guidance estimates a revenue growth of 12% for the second half of 2014, driven by new product launches[19]. - The company has established a significant investment plan post-IPO to support its strategic development and enhance its competitive position in the antibiotic industry[61]. - The total amount of raised funds is ¥478,884.23 million, with ¥454,890.93 million already invested cumulatively[75]. - The company has committed to a total of CNY 149,107.33 million in various projects, with CNY 112,017.11 million already utilized[78]. - The company has made several equity acquisitions, including CNY 24,650 million for Zhejiang Guojing and CNY 42,600 million for Junjian Plastic[79]. Operational Efficiency - The gross margin for the first half of 2014 was reported at 45%, a slight decrease from 47% in the previous year[19]. - Operating costs increased to ¥2,297,385,511, a rise of 31.78%, primarily due to expanded operational scale and lower capacity utilization during the trial production phase of the thiocyanate erythromycin production line[35]. - The company has implemented lean management across ten production facilities, resulting in over 100 lean projects and a 70% implementation rate of 5S practices[52]. - The company has focused on quality management improvements post-GMP certification, enhancing risk control and product safety measures[51]. - The company has adjusted its marketing strategy and product structure in response to changes in market conditions affecting product sales prices[79]. Compliance and Governance - The company is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure regulations related to transactions with a related party[111]. - The company received an administrative penalty from the China Securities Regulatory Commission on June 3, 2014, due to undisclosed related party transactions, resulting in fines and warnings[110]. - The company has taken corrective measures in response to the China Securities Regulatory Commission's directives regarding information disclosure and related party transactions[107]. - The company has made commitments to ensure no high-risk investments for twelve months following the replenishment of working capital[136]. - The company has committed to maintaining the independence of its operations and securing raw material supplies for its antibiotic projects[136]. Shareholder Information - The profit distribution plan for 2013 includes a cash dividend of RMB 2.50 per 10 shares and a capital reserve conversion of 5 shares for every 10 shares held, approved by the shareholders' meeting on May 21, 2014[100]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[103]. - The total number of ordinary shareholders at the end of the reporting period was 30,172[144]. - The number of shares with limited sale conditions decreased by 633,780, resulting in a total of 243,408,400 shares, representing 50.71% of total shares[144]. - The number of shares with unlimited sale conditions increased by 633,780, resulting in a total of 236,591,600 shares, representing 49.29% of total shares[144].

Financial Performance - The company's operating revenue for 2013 was CNY 6,831,281,981, representing a 16.07% increase compared to CNY 5,885,278,617 in 2012[22]. - The net profit attributable to shareholders for 2013 was CNY 1,079,521,586, a slight decrease of 0.74% from CNY 1,087,515,748 in 2012[22]. - The net cash flow from operating activities increased significantly by 160.79% to CNY 1,050,373,845 from CNY 402,771,467 in 2012[22]. - The total assets at the end of 2013 reached CNY 17,946,851,434, up 20.2% from CNY 14,930,778,241 at the end of 2012[22]. - The net assets attributable to shareholders increased by 10.87% to CNY 9,759,926,168 from CNY 8,802,834,955 at the end of 2012[22]. - The basic earnings per share for 2013 was CNY 2.25, a decrease of 0.88% from CNY 2.27 in 2012[22]. - The weighted average return on equity for 2013 was 11.64%, down from 13.11% in 2012[22]. - The company’s total cost of sales was CNY 3,712,055,490, marking a 10.01% increase from CNY 3,374,228,753 in 2012[82]. - Financial expenses rose by 77.61% to CNY 163,664,500, primarily due to increased debt from bonds and bank loans[85]. Dividend Policy - The company plans to distribute a cash dividend of 2.50 CNY per 10 shares (including tax) to all shareholders based on the total share capital as of December 31, 2013[4]. - The company has maintained a consistent cash dividend policy, distributing a total of 120 million yuan in cash dividends for 2013, which is 11.12% of the net profit attributable to shareholders[159]. - The proposed profit distribution for 2013 includes a cash dividend of 2.5 yuan per 10 shares and a capital reserve increase of 5 shares per 10 shares[160]. - The company has successfully implemented cash dividends for three consecutive years since its listing, reflecting a commitment to investor returns[156]. - The company has established a comprehensive cash dividend policy that meets regulatory requirements and enhances shareholder engagement[154]. Research and Development - The company invested over 400 million yuan in R&D in 2013, an increase of approximately 99.74% compared to the previous year[36]. - The company has a total of 557 product varieties with 924 specifications, including 108 varieties of infusion products[33]. - By the end of 2013, the company held 1,144 patents, including 126 invention patents[33]. - The company registered 55 projects in 2013, with 42 classified as A-class projects, focusing on areas such as oncology and diabetes[43]. - The company is actively pursuing new product development, with a total of 40 products listed for production or clinical trial applications, indicating a robust pipeline[47]. - The company aims to enhance its market position in oncology with several first generic drugs, including Afatinib and Cabazitaxel, currently in the clinical trial phase[46]. - The company has submitted applications for several electrolyte replenishment products, such as Sodium Acetate Ringer's Injection, to strengthen its portfolio in this area[46]. - The company is focusing on expanding its product line in the diabetes treatment sector, with several first generic drugs submitted for clinical trials, including Saxagliptin and Canagliflozin[46]. Internal Control and Governance - The company reported significant internal control deficiencies regarding the identification of related party transactions, impacting the accuracy and completeness of financial statements[5]. - The company plans to enhance internal control and governance in response to an investigation by the China Securities Regulatory Commission[34]. - The company has acknowledged the need for corrective measures and is actively working to address the issues raised by the regulatory authorities[197]. - The company is committed to enhancing compliance and governance by reinforcing the understanding of relevant laws and regulations among its board and management[200]. - The company plans to re-evaluate the decision-making process for related party transactions to ensure compliance with accounting standards and protect minority shareholders[197]. Market and Industry Risks - The company faces risks including industry policy changes, rising production costs, and risks associated with rapid development and fixed asset depreciation[13]. - The company faces risks from industry policy changes and rising production costs, which may impact procurement, manufacturing, and sales[145][146]. - Increased depreciation from new fixed assets is expected to affect profit levels, but the company plans to offset this through product sales[149]. Strategic Initiatives - The company has established a comprehensive product line with 155 ongoing projects, including 48 super A-class projects[42]. - The company aims to maintain its leading position in the infusion market through continuous industrial upgrades and product structure adjustments[32]. - The company is focused on expanding its antibiotic production chain, with the Yili Chuaning project as the leading initiative[131]. - The company plans to enhance its quality management system post-GMP certification, addressing potential quality risks across production facilities[138]. - The company is committed to developing high-quality generic drugs to address major disease treatment issues[133]. Compliance and Regulatory Issues - The company has been under scrutiny for failing to accurately disclose related party transactions, leading to a warning from the Sichuan Regulatory Bureau[197]. - The audit report from KPMG Huazhen provided a qualified opinion on the company's financial statements for 2013, reflecting concerns about the accuracy of disclosures[193]. - The company is required to submit a written report to the Sichuan Regulatory Bureau by May 31, 2013, detailing corrective actions taken in response to the regulatory findings[197]. - The company faced regulatory scrutiny due to non-compliance in the acquisition process, resulting in penalties for several executives, including a fine of 30,000 yuan for the chairman[199]. Acquisitions and Investments - Sichuan Kelun Pharmaceutical Co., Ltd. acquired the original Qingfa Pharmaceutical for a total payment of 148 million yuan, which was considered as settling all debts owed by the original Qingfa Pharmaceutical to Sangwei Biological Company[167]. - The company approved the acquisition of Chongzhou Junjian Plastic Co., Ltd. with a unanimous vote of 5 in favor and 0 against during the board meeting[198]. - The company has completed the absorption merger of Guizhou Jinlun on February 28, 2013, following the approval from the board on November 17, 2012[175]. - The company has dissolved Sichuan Yaobao due to reduced demand for glass bottles, which will not significantly impact overall business development and profitability[126]. Social Responsibility - The company has actively fulfilled its social responsibilities, publishing reports on governance, safety, and environmental protection[160]. - The company does not belong to any heavily polluting industries as defined by national environmental protection regulations[161]. - The company reported no significant social security issues during the reporting period[162]. - There were no administrative penalties imposed on the company during the reporting period[162].

四川科伦药业股份有限公司 2014 年第一季度报告正文 证券代码：002422 证券简称：科伦药业 公告编号：030 四川科伦药业股份有限公司 2014 年第一季度报告正文 1 四川科伦药业股份有限公司 2014 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人刘革新、主管会计工作负责人冯伟及会计机构负责人(会计主管 人员)赖德贵声明：保证季度报告中财务报表的真实、准确、完整。 2 除下列董事外，其他董事亲自出席了审议本次季报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 刘思川 董事 出差 潘慧 董事 出差 于明德 董事 出差 张强 董事 出差 四川科伦药业股份有限公司 2014 年第一季度报告正文 第二节 主要财务数据及股东变化 非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 ...